Clinical Trial Update: A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating erlotinib for leptomeningeal carcinomatosis in EGFR-mutant non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Carcinomatosis
• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Clinical Research Center for Solid Tumor, Korea | Conditions: Leptomeningeal Carcinomatosis, Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED